Overview

Safety and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia

Status:
Terminated
Trial end date:
2012-08-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, efficacy, and pharmacokinetics of milnacipran in pediatric patients aged 13 to 17 years with primary fibromyalgia.
Phase:
Phase 2
Details
Lead Sponsor:
Forest Laboratories
Collaborator:
Cypress Bioscience, Inc.
Treatments:
Levomilnacipran
Milnacipran